Day: June 9, 2023

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

Written by Customer Service on June 9, 2023. Posted in Earnings Releases And Operating Results.

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2023. Recent Highlights (including post period events)Continued progress with FDA De Novo authorization review, with FDA indicating a target date for decision completion by the end of the second calendar quarter of 2023 Secured additional key insurance coverage contracts for KidneyIntelX including:EmblemHealth, covering over three million lives in New York Tri-state region CareFirst BlueCross BlueShield, the largest health care plan in the U.S. Mid-Atlantic regionContinuing...

Aura Declares Dividend of US$0.14 per share to be paid in June 2023

Written by Customer Service on June 9, 2023. Posted in Dividend Reports And Estimates.

ROAD TOWN, British Virgin Islands, June 09, 2023 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) announced today that the Company’s Board of Directors (the “Board”) has declared and approved the payment of a dividend (the “Dividend”) of US$0.14 per common share (approximately US$10.1 million in total). In accordance with the Company’s dividend policy (the “Dividend Policy”), the Dividend is in respect of and is based on Aura’s expected financial results for the six months ending June 30, 2023. Under the Dividend Policy, the Company’s semi-annual dividend is equal to 20% of its estimated Adjusted EBITDA1 for the relevant six months less sustaining capital expenditures and exploration capital expenditures for the same period. The amount of the Dividend is based on the actual...

AS Tallinna Vesi and Nordic Investment Bank signed a loan agreement

Written by Customer Service on June 9, 2023. Posted in Public Companies.

AS Tallinna Vesi and Nordic Investment Bank signed a loan agreement for EUR 40 million. The loan maturity is on 09.06.2038 and the loan can be drawn down until 09.06.2024. The loan agreement is the second half of a financing structure, the first half of which was a syndicated loan agreement signed on 15 May 2023. See Company´s announcement on May 15, 2023. The loan agreements of AS Tallinna Vesi are concluded on a variable interest rate basis based on Euribor. The Company assesses the risks associated with variable interest rates and hedging opportunities on an ongoing basis. The new agreements will increase the average interest rate level of the loan portfolio by 31 basis points. Further changes depend on changes in the base rate and the share of loans drawn down. The signed loan agreements will finance the Company’s investments...

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

Written by Customer Service on June 9, 2023. Posted in Public Companies.

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The data are being presented in a poster today at the European Hematology Association 2023 Hybrid Congress (EHA2023) and will also be featured in an oral presentation at the 17th International Conference on Malignant Lymphoma (17-ICML) being held in Lugano, Switzerland from June 13-17, 2023. “We’re pleased to be sharing updated LOTIS-2 results demonstrating the long‐term efficacy and safety of ZYNLONTA with the lymphoma community...

Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference

Written by Customer Service on June 9, 2023. Posted in Public Companies.

SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the Jefferies Global Healthcare Conference:Jefferies Global Healthcare ConferenceFireside Chat: June 9, 2023 at 11:00 a.m. ETNew York, NYThe live and archived webcast, and along with the most recent Iovance corporate presentation, will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the...

Teekay Corporation Announces Update on $30 Million Share Repurchase Program and Announces New Share Repurchase Program

Written by Customer Service on June 9, 2023. Posted in Public Companies.

HAMILTON, Bermuda, June 09, 2023 (GLOBE NEWSWIRE) — Teekay Corporation (Teekay or the Company) (NYSE:TK) today announced that the Company has repurchased 4.40 million common shares for a total of $25.0 million under its previously-announced $30 million share repurchase program, which equates to an average price of $5.67 per share. Since August 2022, Teekay has repurchased a total of 10.87 million common shares, or 10.7% of the outstanding common shares immediately prior to commencement of the initial share repurchase plan announced in August 2022, for a total cost of $55.0 million, representing an average repurchase price of $5.06 per share. In addition, the Company’s Board of Directors has authorized a new share repurchase program for the repurchase of up to $25 million of the Company’s outstanding common shares. Under the program,...

NIO Inc. Reports Unaudited First Quarter 2023 Financial Results

Written by Customer Service on June 9, 2023. Posted in Earnings Releases And Operating Results.

Quarterly Total Revenues reached RMB10,676.5 million (US$1,554.6 million)iQuarterly Vehicle Deliveries were 31,041 units SHANGHAI, China, June 09, 2023 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced its unaudited financial results for the first quarter ended March 31, 2023. Operating Highlights for the First Quarter of 2023Vehicle deliveries were 31,041 in the first quarter of 2023, consisting of 10,430 premium smart electric SUVs and 20,611 premium smart electric sedans, representing an increase of 20.5% from the first quarter of 2022, and a decrease of 22.5% from the fourth quarter of 2022.Key Operating Results 2023 Q1 2022 Q4 2022 Q3 2022 Q2Deliveries 31,041 40,052 31,607 25,059 2022...

Form 8.3 – [EMIS GROUP PLC ] 08 06 2023 – (CGWL)

Written by Customer Service on June 9, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Announcement of Currency Exchange Option

Written by Customer Service on June 9, 2023. Posted in Public Companies.

VEON Holdings B.V. Announcement of Currency Exchange Option Amsterdam, 9 June 2023 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, today provides some further details regarding our ruble denominated notes. We would like to reiterate the currency election terms for the holders of the following ruble denominated notes: RUB10,000,000,000 6.50% Senior Unsecured Notes;RUB20,000,000,000 6.30% Senior Unsecured Notes; andRUB20,000,000,000 8.125% Senior Unsecured Notes (the “Notes”) Each issued under the U.S.$6,500,000,000 Global Medium Term Note Programme (the “Programme”) of VEON Holdings B.V. (the “Issuer”)RUB10,000,000,000 6.50% due 2025Regulation S Global Note: 222671639 / Rule 144A Global Note: 222671299Regulation S Global Note: XS2226716392...

Extraordinary General Meeting of Infant Bacterial Therapeutics

Written by Customer Service on June 9, 2023. Posted in Public Companies.

At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors’ resolution from May 16, 2023 to increase the company’s share capital through the issuance of new shares with pre-emptive rights for the company’s shareholders. Subscription may also be made without pre-emptive rights, as set forth in the complete issue resolution. Through the rights issue, IBT’s share capital will increase with not more than approximately SEK 611,932 through the issue of not more than 75,547 new class A shares and 2,169,689 new class B shares. The record date for the right to participate in the rights issue is June 13, 2023. Subscription for shares shall be made during the period June 15 to June 29, 2023. The subscription price is SEK 45 per share, irrespective of share class. For...

Day: June 9, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals